15
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Drug Design, Development and Therapy (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the design and development of drugs, as well as the clinical outcomes, patient safety, and programs targeted at the effective and safe use of medicines. Sign up for email alerts here.

      88,007 Monthly downloads/views I 4.319 Impact Factor I 6.6 CiteScore I 1.12 Source Normalized Impact per Paper (SNIP) I 0.784 Scimago Journal & Country Rank (SJR)

       

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardioprotective activity of placental growth factor combined with oral supplementation of l-arginine in a rat model of acute myocardial infarction

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Exogenous administration of placental growth factor (PlGF) stimulates angiogenesis and improves ventricular remodeling after acute myocardial infarction (AMI), and supplementation with l-arginine ameliorates endothelial function. The objective of the present study was to compare the cardioprotective effects of combination therapy of PlGF and l-arginine with those of direct administration of PlGF alone in a rat model of AMI.

          Materials and methods

          Fifty male Sprague Dawley rats were randomly divided into five groups: sham group, normal saline group, l-arginine group, PlGF group, and combination group (PlGF + l-arginine). An AMI rat model was established by ligation of the left anterior descending of coronary arteries. After 4 weeks of postligation treatment, cardiac function, scar area, angiogenesis and arteriogenesis, myocardial endothelial nitric oxide synthase (eNOS) and collagen I protein content, and plasma concentration of brain natriuretic peptide (BNP) were studied. Echocardiography, Masson’s staining, immunohistochemical analyses, Western blot, and enzyme-linked immunosorbent assay were performed.

          Results

          Left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), and capillary and arteriole densities were higher in the PlGF group than in the normal saline group ( P<0.01). Scar area, collagen I protein content, and plasma concentration of BNP were decreased in the PlGF group ( P<0.01). Myocardial eNOS protein level was elevated in the l-arginine group and PlGF + l-arginine group ( P<0.01). Compared with the PlGF group, LVEF, LVFS, myocardial eNOS, and capillary and arteriole densities were higher in the combination group ( P<0.01). Scar area, content of collagen I protein, and plasma concentration of BNP were reduced in the combination group ( P<0.01).

          Conclusion

          Exogenous administration of PlGF stimulates angiogenesis and improves cardiac function. l-arginine increases the expression of the eNOS protein. PlGF and l-arginine have a more pronounced, synergistic protective effect on myocardial protection compared with that of exogenous PlGF therapy alone.

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

          The therapeutic potential of placental growth factor (PlGF) and its receptor Flt1 in angiogenesis is poorly understood. Here, we report that PlGF stimulated angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to vascular endothelial growth factor (VEGF). An antibody against Flt1 suppressed neovascularization in tumors and ischemic retina, and angiogenesis and inflammatory joint destruction in autoimmune arthritis. Anti-Flt1 also reduced atherosclerotic plaque growth and vulnerability, but the atheroprotective effect was not attributable to reduced plaque neovascularization. Inhibition of VEGF receptor Flk1 did not affect arthritis or atherosclerosis, indicating that inhibition of Flk1-driven angiogenesis alone was not sufficient to halt disease progression. The anti-inflammatory effects of anti-Flt1 were attributable to reduced mobilization of bone marrow-derived myeloid progenitors into the peripheral blood; impaired infiltration of Flt1-expressing leukocytes in inflamed tissues; and defective activation of myeloid cells. Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb.

            We have previously shown that monocytes adhere to the vascular wall during collateral vessel growth (arteriogenesis) and capillary sprouting (angiogenesis). In this study we investigated the association of monocyte accumulation with both the production of the cytokines-basic fibroblast growth factor (bFGF) and TNF-alpha-and vessel proliferation in the rabbit after femoral artery occlusion. In particular, we studied the effects of an increase in monocyte recruitment by LPS on capillary density as well as collateral and peripheral conductance after 7 d of occlusion. Monocytes accumulated around day 3 in collateral arteries when maximal proliferation was observed, and stained strongly for bFGF and TNF-alpha. In the lower limb where angiogenesis was shown to be predominant, macrophage accumulation was also closely associated with maximal proliferation (around day 7). LPS treatment significantly increased capillary density (424+/-26.1 n/mm2 vs. 312+/-20.7 n/mm2; P < 0.05) and peripheral conductance (109+/-33.8 ml/min/100 mmHg vs. 45+/-6.8 ml/min/100 mmHg; P < 0.05) as compared with untreated animals after 7 d of occlusion. These results indicate that monocyte activation plays a major role in angiogenesis and collateral artery growth.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Matricellular proteins: an overview

              Matricellular proteins are secreted into the extracellular environment, or matrix, but do not play a primary structural role in this location. Rather, these proteins modulate cell function by interacting with cell-surface receptors, proteases, hormones, and other bioeffector molecules, as well as with structural matrix proteins such as collagens. The term ‘matricellular’ was introduced to explain the unusual diversity of functions that were beginning to be recognized in proteins such as thrombospondin-1(TSP-1), SPARC, and tenascin-C. (Sage and Bornstein 1991; Bornstein 1995). The intent of segregating this subclass of secreted proteins was to emphasize that the extracellular environment was a major factor in regulating their synthesis, a process that had been termed ‘dynamic reciprocity’ at an earlier date (Bornstein et al. 1982). A review that summarized many of the considerations that led to the concept of matricellular proteins was published in Methods in Cell Biology (Bornstein 2002). In additional reviews (Bornstein 2001; Bornstein and Sage 2002) some of the distinguishing characteristics of matricellular proteins were summarized in greater detail. These included: 1) high levels of expression during development and in response to injury; 2) binding to many cell-surface receptors, components of the extracellular matrix, growth factors, cytokines, and proteases; 3) induction of de-adhesion or counter-adhesion in contrast to the adhesivity of most matrix proteins (Murphy-Ullrich 2001; Liu et al. 2009), and 4) a grossly normal or subtle phenotype that is observed in mice with a targeted disruption (knockout) of some matricellular protein genes. The complexity of the functions of most matricellular proteins results from the fact that these functions are, in large part, contextual, i.e. they derive from the different structural proteins, cell-surface receptors, proteases, and cytokines with which these proteins come in contact in the local environment of different tissues. The unexpected phenotypes of some matricellular protein-null mice have provided clues to the functions of matricellular proteins. Thus, for example, the abnormally shaped and sized collagen fibrils observed in TSP-2-null mice in skin and other connective tissues led to the demonstration that TSP-2 functions as a clearance factor for MMP2 in the pericellular environment (Yang et al. 2001). In turn, the elevated MMP2 levels in the pericellular environment of TSP2-null mice reduced tissue transglutaminase activity and the collagen crosslinks generated by this enzyme (Agah et al. 2005). As another example, the cataracts and increased adipogenesis encountered in SPARC-null mice led to a better understanding of extracellular matrix assembly (Brekken and Sage 2000) and SPARC signaling pathways (Nie and Sage 2009). Although a useful review of the functions of a limited number of matricellular proteins in bone biology has been published (Alford and Hankenson 2006), and Sangaletti and Colombo (2008) have surveyed the functions of matricellular proteins in inflammation and cancer, this issue of the JCCS provides a more comprehensive coverage of the field and takes advantage of recent mechanistic information that improves our understanding of how matricellular proteins function. Thus, for TSPs, Bornstein has described the mechanisms that enable TSP-1 and TSP-2 to function as both angiogenic and anti-angiogenic proteins, and the potential clinical applications of these properties; Hankenson and Delany consider the roles of TSP-2 and SPARC in bone formation; Lawler describes the effects of TSPs on the structure of the extracellular matrix; MacLauchlan and Kyriakides review the role of TSPs in wound healing, ischemia, and the foreign body response; and Schellings et al. review the roles of TSPs in cardiac remodeling. For SPARC and members of the SPARC family, Bradshaw discusses the role of SPARC in extracellular matrix assembly; Arnold and Brekken consider the role of SPARC as a regulator of tumorigenesis, and Nie and Sage summarize the evidence for SPARC as an inhibitor of adipogenesis. Some matricellar proteins are represented by single presentations. Lund et al. present the role of osteopontin in inflammatory proceses; Midwood and Orend consider the role of tenascin-C in tissue injury and tumorigenesis; Norris et al. describe the many facets of the effects of periostin on cardiac development, remodeling, and pathophysiology ; Merline et al. present evidence for the matricellular functions of small leucine-rich proteoglycans (SLRPS), and Yanagisawa et al. present data supporting the inclusion of fibulin-5 in the matricellular protein family. Finally, Eroglu summarizes the evidence for the roles of matricellular proteins in the development and function of the nervous system. Clearly, the articles mentioned above do not cover all the proteins that are now considered to be matricellular. Prominent among those not included in this review are several members of the CCN (Cyr-61, Connective tissue growth factor, and Nov family of proteins that were recently reviewed (Chen and Lau 2009; Holburn et al. 2008; and Yeger and Perbal 2007), tenascin- X (Zweers et al. 2004), the galectins (Elola et al. 2007), plasminogen activator inhibitor type 1 (PAI-1) (Maquerlot et al. 2006), and autotaxin (Dennis et al. 2008). An issue that has not been addressed in the categorization of matricellular proteins is whether to include matrix proteins, the matricellular function of which, as defined above, is revealed only when fragments of the proteins are investigated. It is now commonly recognized that new functions, not present in the intact protein, can be generated by limited physiological proteolysis (Sage 1997; Davis et al. 2000). However, it would seem preferable at this time, in the interest of brevity, to limit our discussion to matrix proteins with matricellular properties that are expressed in the intact proteins. A PubMed search of the literature, performed at the end of the 2008 calendar year, revealed that there were 348 publications that used the term ‘matricellular’ in the title and/or abstract since its first use in 1995. The increase in recent years has been almost exponential, with 65 citations listed during 2008. A number of these citations concern proteins with credentials as matricellular proteins that are incomplete or questionable, but it is reasonable to expect that the list of matricellular proteins will grow as more information is gathered about other extracellular proteins with non-structural functions.
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                Drug Design, Development and Therapy
                Dove Medical Press
                1177-8881
                2016
                28 October 2016
                : 10
                : 3483-3492
                Affiliations
                [1 ]Department of Cardiology
                [2 ]Department of Oncological Radiotherapy, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, People’s Republic of China
                Author notes
                Correspondence: Wei Wu, Department of Cardiology, The Fifth Affiliated Hospital of Sun Yat-Sen University, No 52, East Meihua Road, Zhuhai, Guangdong 519000, People’s Republic of China, Tel +86 139 0307 5931,, Email wuwei9@ 123456mail.sysu.edu.cn
                [*]

                These authors contributed equally to this work

                Article
                dddt-10-3483
                10.2147/DDDT.S117683
                5094604
                27822012
                4c3ab53a-0bce-4f4f-b35a-41bf5064dbb8
                © 2016 Luo et al. This work is published and licensed by Dove Medical Press Limited

                The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                History
                Categories
                Original Research

                Pharmacology & Pharmaceutical medicine
                placental growth factor,l-arginine,acute myocardial infarction,angiogenesis

                Comments

                Comment on this article